BTG boasts of higher sales on drugs success

SPECIALIST healthcare firm BTG said yesterday that its overall financial performance in the first half has been “well ahead of expectations”.

Its licensing and biotechnology business reported a strong performance, driven by the regulatory approvals for its ZYTIGA drug and a good showing by BeneFIX.

As a result, BTG now expects sales in the six months to 30 September to total between £160m and £165m, significantly higher than the current consensus forecast of £139.6m.